CDH1 rs121964875: Understanding This Genetic Variant
The rs121964875 variant is a single nucleotide polymorphism located within the CDH1 gene. It has been identified in clinical research databases in the context of hereditary cancer-predisposing syndromes.
What each genotype means
Typical genetic profile
This genotype represents the common state for this location in the genome. There is no established clinical significance or disease association linked to this specific genetic sequence in current research databases.
This is the most common genotype observed in the general population.
Variant carrier status
This genotype has been identified in clinical research databases, though it is often flagged as a potential miscall in direct-to-consumer testing. While some literature has historically associated this variant with gastric cancer predisposition, the clinical evidence remains limited and requires professional medical validation.
This genotype is rare in the general population and is not consistently reported across major ancestry groups.
Documented variant profile
This genotype is recorded in clinical databases as a known variant at this position. Its presence does not inherently indicate a clinical diagnosis, and its functional impact remains poorly characterized in current scientific literature.
This genotype is observed in clinical research cohorts but is not common in the general population.
What is rs121964875?
The rs121964875 variant is a specific change in the DNA sequence, technically classified as a single nucleotide polymorphism (SNP). It is located on chromosome 16 at position 68,738,307 (GRCh38). In the context of human genomics, SNPs are the most common type of genetic variation, representing a difference in a single building block of DNA, known as a nucleotide. While many SNPs are benign and have no effect on health, others are studied for their potential to influence biological processes or disease susceptibility. This particular variant is situated within the CDH1 gene, which provides instructions for making a protein called E-cadherin. E-cadherin is essential for cells to stick together to form organized tissues. Because this variant is located within a gene that plays a critical role in cell adhesion and tumor suppression, it has been the subject of clinical investigation regarding its potential impact on cellular function.
The Role of the CDH1 Gene
The CDH1 gene is responsible for producing the E-cadherin protein. This protein acts like a molecular glue, allowing epithelial cells—the cells that line the surfaces of organs and structures throughout the body—to adhere to one another. Beyond its structural role, E-cadherin is a well-characterized tumor suppressor. By maintaining the integrity of cell-to-cell junctions, it helps prevent cells from detaching and migrating, a process that is a hallmark of cancer development. When the CDH1 gene is altered, the resulting E-cadherin protein may be dysfunctional or absent, which can compromise the structural stability of tissues. Research into CDH1 has primarily focused on its association with hereditary diffuse gastric cancer and lobular breast cancer. Because of its vital role in maintaining tissue architecture, variants within this gene are scrutinized for their potential to disrupt these protective mechanisms, potentially increasing the risk of certain malignancies.
Research Associations and Evidence
Clinical research databases have documented rs121964875 in relation to hereditary cancer-predisposing syndromes. However, it is important to interpret this information with caution. Genetic associations are often complex, and the presence of a specific variant does not automatically guarantee the development of a disease. Some reports in the literature have flagged specific genotypes, such as the A;G genotype, as potential miscalls by certain consumer genetic testing platforms. This highlights the necessity of clinical-grade validation for any genetic finding. The evidence strength for this variant is currently considered moderate, meaning that while it has been identified in clinical contexts, further peer-reviewed studies are required to fully understand its penetrance and clinical significance. Genomic science is an evolving field, and as more data is collected, our understanding of how this specific variant interacts with other genetic and environmental factors will likely become more precise.
Navigating Your Genetic Information
If you have received information about the rs121964875 variant from a genetic test, it is essential to understand what you can and cannot do with this data. First and foremost, this information should never be used to self-diagnose or make medical decisions. Genetic testing results, especially those from direct-to-consumer services, can sometimes contain errors or require specialized interpretation that only a qualified healthcare professional can provide. If you are concerned about your risk for hereditary cancer syndromes, the most appropriate step is to consult with a genetic counselor or a physician. They can help you understand the clinical relevance of your results, discuss the limitations of the testing performed, and determine if further diagnostic testing is necessary. Genetic information is a tool for informed discussion with your medical team, not a substitute for professional clinical evaluation and personalized medical advice.
How common is this variant?
The population frequency for this variant is not specified in standard catalogs, and it is often identified through clinical case reports rather than broad population studies.
Frequently asked questions
Is rs121964875 a cause of cancer?
Genetic variants are rarely the sole cause of cancer. While rs121964875 is associated with hereditary cancer-predisposing syndromes, its presence does not mean an individual will definitely develop cancer.
Should I be worried if I have this variant?
Do not panic if you see this variant in a report. Many genetic variants are benign, and even those with clinical significance require professional interpretation to understand their actual impact on your health.
Can I trust my consumer genetic test results for this SNP?
Consumer genetic tests are not always as accurate as clinical-grade diagnostic tests. Some literature suggests that certain genotypes for this SNP may be miscalled by consumer platforms, so clinical validation is recommended.
Who should I talk to about my genetic results?
You should discuss any genetic findings with a certified genetic counselor or your primary care physician. They are trained to interpret these results within the context of your personal and family medical history.
Sources & further reading
Educational information only, last refreshed 10/1/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121964875?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants
This variant in the HLA-DQB1 region is associated with peanut allergy susceptibility, reflecting the broader role of HLA class II variation in food allergy risk.
This variant is a robustly replicated genetic marker associated with short sleep duration across diverse ancestral populations.
This variant in the TYK2 gene is identified as a shared causal signal in the genetic architecture of psoriasis and rheumatoid arthritis.
This TYK2 variant shows evidence of antagonistic pleiotropy, with opposite effects on the risk of psoriasis versus rheumatoid arthritis.
This SNP acts as an intermediate allele tag for the C9orf72 repeat expansion, which is linked to both ALS risk and longevity outcomes.
This variant in the CDKN2B-AS1 long noncoding RNA gene is associated with extreme longevity in genome-wide association studies.